|
" Small Cell Carcinomas : "
Jonathon G Maldonado
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
800243
|
| Doc. No
|
:
|
b620304
|
| Main Entry
|
:
|
Jonathon G Maldonado
|
| Title & Author
|
:
|
Small Cell Carcinomas : : Causes, Diagnosis and Treatment.\ Jonathon G Maldonado
|
| Publication Statement
|
:
|
New York: Nova Science Publishers, Incorporated, 2010
|
| Series Statement
|
:
|
Cancer etiology, diagnosis, and treatments.
|
| Page. NO
|
:
|
(250 pages).
|
| ISBN
|
:
|
1617285803
|
|
|
:
|
: 9781617285806
|
| Notes
|
:
|
Radiotherapy for Small CellLung Cancer.
|
| Contents
|
:
|
SMALL CELL CARCINOMAS:CAUSES, DIAGNOSIS AND TREATMENT; Contents; Preface; Gene Silencing Therapy in Small CellLung Cancer --; Which Agents, Targets, and Delivery Systems?; Abstract; Abbreviations list; Introduction; 1.1. Cancer Genes as Potential Targets of Therapeutic Gene Silencing; 1.1.1. Oncogenes and tumor suppressor genes; 1.1.2. MicroRNAs; 1.1.3. The "hallmarks" of tumorigenic phenotype; 1.1.4. Opportunities for therapeutic intervention; 1.2. Gene Silencing Agents: A Novel Class of Drug Molecules; 1.2.1. Antisense oligodeoxynucleotides; 1.2.2. Ribozymes and DNAzymes. 1.2.3. RNA interference2. The Challenge of Target Validation in SCLC; 3. Potential Targets for Therapeutic GeneSilencing in SCLC; 3.1. Anchorage-Independency and Anchorage Signaling; 3.1.1. Integrins and chemokine receptors; 3.1.2. Autocrine loops 1 --; G-protein coupled receptors and downstreameffectors; 3.1.3. Autocrine loops 2 --; receptor tyrosine kinases and downstreameffectors; 3.2. Key Proteins in Important Cellular Signaling Pathways in SCLC; 3.2.1. Protein kinase C family; 3.2.2. PI3K/Akt pathway; 3.2.3. Focal adhesion kinase family; 3.2.4. Scr family; 3.2.5. Ras family. 3.3. Limitless Replicative Potential3.3.1. Telomerase; 3.3.2. Hedgehog signaling pathway; 3.3.3. Urokinase plasminogen activator; 3.4. DNA Stability, Repair and Replication; 3.4.1. RAD51; 3.4.2. E2F1; 3.4.3. S-phase kinase associated protein 2; 4. Lessons to Take from the Validation of ClassicalOncogenes as Therapeutic Targets in SCLC; 4.1. Myc Family; 4.2. Bcl-2 Family; 4.2.1. Bcl-2 in SCLC prognosis; 4.2.2. In vitro modulation of Bcl-2; 4.2.3. Oblimersen: an anti-Bcl-2 antisense ODN in clinical evaluation; 4.2.4. Bcl-xL and multitargeting of anti-apoptotic proteins. 5. Delivery of Gene Silencing Agents in SCLC6. Conclusion; Acknowledgments; References; Small Cell Carcinomas: Contributionof Cytologic Tools to Diagnosisand Management; Abstract; Introduction; Small Cell Lung Cancer (SCLC); Cytodiagnostic Tools for SCLC; Frequency of Small Cell Lung Carcinoma in Cytologic Material; Cytomorphology of SCLC; Extrapulmonary Small Cell Carcinoma (EPSCC); Skin; Cervix; Urinary bladder; Gastrointestinal Tract; Breast; Head and Neck Region; Metastatic Lesions of SCC; Efficacy of Cytology in Diagnosisof SCLC and EPSCC. Limitations of Cytomorphology andDifferential Diagnostic ProblemsMorphologic Variants of SCC; SCLC vs. Carcinoid Tumor; SCLC vs. EPSCC; SCLC vs. NSCC of Lung; Association with Other Neoplasms with SCLC and EPSCC; Place of SCLC and EPSCC in the Spectrum of SRCT; Contribution of Ancillary Studies; Carcinomas of Lung; SCLC vs. EPSCC; Merkel Cell Carcinoma (MCC) of Skin; SCC of Breast; SCC of Esophagus; SCC of Stomach; SCC of Ovary; SCC of Endometrium; SCC of Cervix; SCC of Urinary Bladder; SCC of Prostate; SCC of Stomach; Role of Cytology in Management; References.
|
| Subject
|
:
|
Bladder -- Cancer.
|
| Subject
|
:
|
Neuroendocrine tumors.
|
| Subject
|
:
|
Small cell lung cancer.
|
| LC Classification
|
:
|
RC280.L8J663 2010
|
| Added Entry
|
:
|
Jonathon G Maldonado
|
|
|
:
|
Mikayla K Cervantes
|
| |